RTTR Ritter Pharmaceuticals Inc.

0.3
+0.01  (+2%)
Previous Close 0.3
Open 0.28
Price To Book -1.16
Market Cap 2,832,798
Shares 9,426,950
Volume 683,780
Short Ratio
Av. Daily Volume 1,129,040
Stock charts supplied by TradingView

NewsSee all news

  1. Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives

    LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to

  2. Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

    LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data failed to meet primary endpoint - September 12, 2019.
RP-G28
Lactose intolerance

Latest News

  1. Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives

    LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to

  2. Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

    LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to